A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Nab-Paclitaxel
Sponsor: Hoffmann-La Roche